《新股消息》錦欣生殖(01951.HK)公開發售獲近百倍認購上限8.54元定價
明日(25日)掛牌上市的錦欣生殖(01951.HK)公布配發結果,發售價定於每股8.54元,為其招股價區間上限,料集資淨額28.08億元,早前公司公布,集資所得約25%用於拓展及升級中國網絡的現有輔助生殖醫療機構及招聘醫療專業人士,20%用於目前無經營的內地省份的額外輔助生殖醫療機構潛在收購,10%用於投資研發,20%用於輔助生殖服務服務鏈的輔助生殖服務提供商及業務潛在收購,15%用於改善品牌專注度以及中國及美國對輔助生殖服務的整體專注,其餘餘下10%用於營運資金及一般企業用途。
公司提供人工授孕服務,其公開發售部分錄得99.26倍認購,即超購98.26倍,經重新分配後,相關部分最終發售股份數目近1.43億股,佔全球發售之40%;另國際發售部分亦獲大幅超額認購。每手2,000股,一手中籤率65%。摩根士丹利和中信里昂證券擔任聯席保薦人。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.